Clinical trials: Renal Failure Chronic
Chronic Kidney Disease Stage 3
A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)
The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD).
- Trial name
- UC-MSC-CKD (NCT06721143)
- Testing
- AION-301
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- AION Healthspan, Inc.
Renal Failure Chronic
Immunotherapy of Chronic Kidney Failure
Kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self.
- Trial name
- NCT04377243
- Testing
- V8
- Where
- Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
End Stage Renal Disease, End Stage Renal Disease on Dialysis
First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings
This is a non-significant risk study utilizing a device cleared for use by the FDA under its 510(k) clearance. Consented patients will complete their usual dialysis treatment under professional care in an ICHD (In-Center…
- Conditions
- End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease
- Trial name
- NCT06581393
- Testing
- Moda-flx Hemodialysis System
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Diality Inc.
Hyperphosphatemia
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
This is a randomized, double-blind, placebo-controlled study to evaluate the effect of tenapanor on change in s-P levels when tenapanor is administered orally, twice daily for 28 days as adjunctive therapy to ESRD subjects with…
- Trial name
- NCT03824587
- Testing
- Tenapanor, Phosphate Binder Agents
- Where
- 48 sites in United States
- Volunteers
- 236 people
- Sponsor
- Ardelyx
Anemia of Chronic Kidney Disease
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
A mass balance study to determine the routes and rates of elimination of radioactivity, to determine total radioactivity in plasma and whole blood over time and compare levels to JTZ-951 and drug-derived entities in plasma and to…
- Trial name
- NCT02805244
- Testing
- JTZ-951, 14C-JTZ-951
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Shionogi Inc.
Cardiac Decompensation
Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices
This is planned as a feasibility study. The objective is to evaluate a specially designed patient adherence and monitoring software on standard mobile devices in remote monitoring of heart failure patients.
- Trial name
- REMOTE-HF-1 (NCT01430936)
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 51 people
- Sponsor
- Aventyn, Inc.
IgA Nephropathy
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
The primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2…
- Trial name
- NCT03608033
- Testing
- OMS721, Vehicle (D5W or saline)
- Where
- 139 sites in United States, Argentina and 21 more
- Volunteers
- 360 people
- Sponsor
- Omeros Corporation
End Stage Renal Disease
Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
- Trial name
- RMFPC-12 (NCT02636049)
- Testing
- Triferic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rockwell Medical Technologies, Inc.
Chronic Kidney Disease, Renal Impairment
A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD). The kidneys filter extra water and waste out of the blood and make urine.
- Conditions
- Chronic Kidney Disease, Renal Impairment, Healthy Volunteers
- Trial name
- NCT05515432
- Testing
- Single oral dose of BAY3283142 IR (immediate release) tablet
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Bayer
Hyperphosphatemia, ESRD
Phosphate Kinetic Modeling 2
The study aims to investigate the concept of computer based Phosphate Kinetic Modeling (PKM) in the hemodialysis patient population.
- Trial name
- PKM2 (NCT01252771)
- Testing
- PKM Algorithm
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Fresenius Medical Care North America
End-Stage Renal Disease (ESRD)
Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis
Chronic inflammation in dialysis patients is linked to cardiovascular mortality and clinical signs and symptoms, like the impaired response to erythropoiesis-stimulating agents (ESAs).
- Trial name
- CIEPO-PILOT (NCT01526798)
- Testing
- Theralite (high cut-off hemodialysis), Conventional high-flux dialyzer
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Vantive Health LLC
Magnetic Resonance Imaging, Chronic Kidney Diseases
Study of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging
Polysaccharide super paramagnetic ferric oxide injection is an iron supplement developed for patients with iron deficiency anemia. Due to its characteristics, it has the potential to be a contrast agent.
- Trial name
- NCT05687864
- Testing
- Polysaccharide superparamagnetic ferric oxide injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Secondary Hyperparathyroidism, Chronic Kidney Disease
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
The primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH) levels by > 30% from baseline among participants…
- Trial name
- NCT03299244
- Testing
- Etelcalcetide, Cinacalcet
- Where
- 90 sites in China, Hong Kong and 4 more
- Volunteers
- 637 people
- Sponsor
- Amgen
Chronic Kidney Disease, Chronic Renal Disease
Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate
The purpose of this study is to look at how the dose of dialysis is affected by the rate at which dialysate flows through the dialyzer.
- Trial name
- NCT00962000
- Testing
- Dialysis Flow Rate Start 600mL/min, Dialysis Flow Rate Start 800mL/min
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vantive Health LLC
Kidney Diseases, Kidney Diseases, Chronic
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN).
- Conditions
- Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
- Trial name
- NCT06858319
- Testing
- zigakibart
- Where
- 26 sites in United States, Argentina and 7 more
- Volunteers
- 220 people
- Sponsor
- Novartis Pharmaceuticals
Renal Failure Chronic Requiring Hemodialysis
Performance Comparison of Revaclear With Larger Dialyzer
The purpose of the study is to show equivalent performance of the Revaclear dialyzer when compared to a dialyzer with larger membrane surface area.
- Trial name
- Revacom HD (NCT01722695)
- Testing
- Dialyzer comparison
- Where
- 2 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Vantive Health LLC
Cardiovascular Diseases, Kidney Failure, Chronic
Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis
The current study will allow the assessment of pharmacokinetics, pharmacodynamics, elimination rate and clearance of dabigatran etexilate during and following haemodialysis in ESRD patients.
- Trial name
- NCT01241539
- Testing
- Dabigatran etexilate
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease (CKD), Hyperkalemia (HK)
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium).
- Trial name
- OPAL (NCT01810939)
- Testing
- Patiromer
- Where
- 58 sites in United States, Croatia and 8 more
- Volunteers
- 243 people
- Sponsor
- Relypsa, Inc.
Complication of Renal Dialysis, End Stage Renal Disease
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an…
- Conditions
- Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD
- Trial name
- ACCESS2 (NCT05425056)
- Testing
- Sirolimus
- Where
- 22 sites in United States, United Kingdom
- Volunteers
- 136 people
- Sponsor
- Vascular Therapies, Inc.
Renal Impairment
Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis
- Trial name
- NCT01464931
- Testing
- Denosumab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Amgen